Intern, Computational Biology

Revolution Medicines • Redwood City, CA

14h • $67,000 - $81,000 • Hybrid

About The Position

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated PhD- or Master’s-level intern to support deployment, optimization, and validation of the FACETS pipeline. Deploy, optimize, and harden the FACETS pipeline for WES and targeted panel tumor/normal datasets. Automate preprocessing, segmentation, and allele-specific copy-number calling workflows. Run large-scale benchmarking and QC evaluations. Integrate FACETS outputs into downstream pipelines.

Requirements

• Current PhD or Master's student in relevant fields.
• Strong understanding of NGS, CN analysis, statistical modeling.

Nice To Haves

• Experience with FACETS or similar tools
• workflow engines
• cloud environments

Responsibilities

• Deploy, optimize, and harden the FACETS pipeline for WES and targeted panel tumor/normal datasets.
• Automate preprocessing, segmentation, and allele-specific copy-number calling workflows.
• Run large-scale benchmarking and QC evaluations.
• Integrate FACETS outputs into downstream pipelines.

What This Job Offers

• Career Level: Intern
• Number of Employees: 251-500 employees